Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-ischemic drug therapy-Luzerner Kantonsspital-silent myocardial ischemia
- Development stage
- Unknown
- Lead developer
- Luzerner Kantonsspital
- Modality
- Small Molecules
01
Overview
This refers to the intensive anti-ischemic drug regimen utilized in the medical therapy arm of the Swiss Interventional Study on Silent Ischemia Type II (SWISSI II) clinical trial. Conducted at Luzerner Kantonsspital and other Swiss centers, the therapy aimed to eliminate or significantly reduce silent myocardial ischemia in asymptomatic patients following a recent myocardial infarction. The regimen consisted of titrated doses of the beta-blocker bisoprolol (5-10 mg/day), the calcium channel blocker amlodipine (5-10 mg/day), and/or the vasodilator molsidomine (4-12 mg twice daily). This pharmacological approach was compared against percutaneous coronary intervention (PCI) to evaluate long-term clinical outcomes, including cardiac death and non-fatal myocardial infarction.
- Other names
- SWISSI II medical therapyintensive anti-ischemic drug therapy
02
Targets
ADRB1 (β1)sGC (Soluble Guanylyl Cyclase)LTCC (Voltage-gated calcium channel (L-type))
Beyond the preview
Go deeper on anti-ischemic drug therapy-Luzerner Kantonsspital-silent myocardial ischemia.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-ischemic drug therapy-Luzerner Kantonsspital-silent myocardial ischemia.